2019-02-14 08:30:00 Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)
RARE: Ultragenyx Pharmaceutical Inc. 2019-01-04 08:30:00 Ultragenyx Announces Positive Topline Results from First Cohort of Phase 1/2 Clinical Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia
This one heading for 100. Let's get this done. Premiums are expensive but anything long term in this is way worth it.
RARE has been consolidating into a textbook falling wedge pattern and is trading just on the underside of the volume point of control. RSI is displaying a bullish divergence and I like this to make a move back near $70 in the next 2-3 months.
Needs back of $86.77 to get back to $117 (IHS bottom)